Skip to main content
MedPathMedPath Home
Clinical Trials/NCT05945524
NCT05945524
Recruiting
Not Applicable

Analysis of the Resistance and Sensitivity Mechanisms to Teclistamab by Focusing on Single Immune Cell Examination

University Hospital, Toulouse18 sites in 1 country100 target enrollmentSeptember 28, 2023
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsMultiple Myeloma

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Multiple Myeloma
Sponsor
University Hospital, Toulouse
Enrollment
100
Locations
18
Primary Endpoint
Response to teclistamab at 12 weeks
Status
Recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSitesSimilar Trials

Overview

Brief Summary

The aim of this study is to discover the immune and oncogenomic features that distinguish patients who respond to teclistamab from patients who are primarily resistant. Moreover, phenotypic and genotypic characteristics that occur with secondary resistance to teclistamab will be analyzed.

Registry
clinicaltrials.gov
Start Date
September 28, 2023
End Date
May 31, 2026
Last Updated
last year
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • •With multiple myeloma
  • •Who receive Teclistamab
  • •Consent form signed

Exclusion Criteria

  • •Patient under legal protection

Outcomes

Primary Outcomes

Response to teclistamab at 12 weeks

Time Frame: at day 1 Cycle 4 (each cycle is 28 days)

response according to International Myeloma Working Group criteria

Study Sites (18)

Loading locations...

Similar Trials

Completed
Not Applicable
Bloodstream Infection of Carbapenem-Resistant Proteus MirabilisProteus Mirabilis InfectionBacteremiaCarbapenem Resistant Bacterial Infection
NCT06542965Dokuz Eylul University67
Recruiting
Not Applicable
Molecular Analysis of Oncogenes and Resistance Mechanisms in Lung CancerLung Neoplasms
NCT01580982University of Colorado, Denver500
Completed
Phase 4
The Immunological Basis for Treatment Resistance to Anti-TNF TreatmentsPsoriasis
NCT01971346University of Michigan50
Unknown
Phase 2
Biomarkers in Urothelial Cancer Patients Treated With PembrolizumabTransitional Cell Carcinoma of the BladderBiomarkers
NCT03263039Erasmus Medical Center80
Not yet recruiting
Not Applicable
Disease causing ability, and medical effects of bacterial infections in ICU to understand challenges and opportunities for prevention.
CTRI/2021/07/035228Manipal Academy of Higher Education Manipal